Institutional Perspectives in Cancer - Hematologic Malignancies: Chaired by Catherine Coombs, MD
Institutional Perspectives in Cancer - Hematologic Malignancies: Chaired by Catherine Coombs, MD
Source: onclive.com
Stay updated with breaking news from Combination Studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Institutional Perspectives in Cancer - Hematologic Malignancies: Chaired by Catherine Coombs, MD
Camonsertib PARPi combinations demonstrated 48% CBR in patients with unmet medical needs, across tumor types, and regardless of PARPi partner or platinum resistance, with a favorable safety and... | April 18, 2023
-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA’s Real-Time Oncology Review (RTOR) Program, Expected in Second Half...